Zobrazeno 41 - 50
of 291
pro vyhledávání: '"Ulrik Lassen"'
Autor:
Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, Anas Gazzah, Ulrik Lassen, Alexander Stein, Patrick Y. Wen, Sascha Dietrich, Maja JA Jonge, Jean-Yves Blay, Antoine Italiano, Kan Yonemori, Daniel C. Cho, Filip YFL de Vos, Philippe Moreau, Elena Elez Fernandez, Jan H. Schellens, Christoph C. Zielinski, Suman Redhu, Vanessa Q. Passos, Palanichamy Ilankumaran, Yung-Jue Bang
Publikováno v:
Cancer Research. 83:CT083-CT083
Beyond melanoma, BRAFV600E alterations are prevalent across multiple tumors. We conducted a basket trial (NCT02034110) to assess efficacy and safety of oral BRAF inhibitor dabrafenib (150 mg BD) plus MEK inhibitor trametinib (2 mg OD) in 206 patients
Autor:
Dorte Schou Nørøxe, Lise Barlebo Ahlborn, Vincent Fougner, Thomas Urup, Benedikte Hasselbalch, Christina Westmose Yde, Hans Skovgaard Poulsen, Ulrik Lassen
Publikováno v:
Cancer Research. 83:1046-1046
Introduction: Glioblastoma (GBM) is an aggressive brain cancer with a median overall survival of 16-24 months. Evaluation of treatment effect can be difficult as pseudo progression is seen in approximately 15% of patients. Hence, effective treatment
Autor:
Christina Westmose Yde, Hans Skovgaard Poulsen, Finn Cilius Nielsen, Ane Y. Schmidt, Jane Skjøth-Rasmussen, Mathias H. Torp, Petra Hamerlik, Ulrik Lassen, Olga Østrup, Signe Regner Michaelsen, Dorte Schou Nørøxe, Savvas Kinalis, Jannick Brennum
Publikováno v:
Molecular Oncology
Molecular Oncology, Vol 14, Iss 11, Pp 2727-2743 (2020)
Nørøxe, D S, Yde, C W, Østrup, O, Michaelsen, S R, Schmidt, A Y, Kinalis, S, Torp, M H, Skjøth-Rasmussen, J, Brennum, J, Hamerlik, P, Poulsen, H S, Nielsen, F C & Lassen, U 2020, ' Genomic profiling of newly diagnosed glioblastoma patients and its potential for clinical utility – a prospective, translational study ', Molecular Oncology . https://doi.org/10.1002/1878-0261.12790
Molecular Oncology, Vol 14, Iss 11, Pp 2727-2743 (2020)
Nørøxe, D S, Yde, C W, Østrup, O, Michaelsen, S R, Schmidt, A Y, Kinalis, S, Torp, M H, Skjøth-Rasmussen, J, Brennum, J, Hamerlik, P, Poulsen, H S, Nielsen, F C & Lassen, U 2020, ' Genomic profiling of newly diagnosed glioblastoma patients and its potential for clinical utility – a prospective, translational study ', Molecular Oncology . https://doi.org/10.1002/1878-0261.12790
Landscape of somatic copy number alterations, mutations, and fusions in selected genes in newly diagnosed glioblastoma patients. The most frequent aberrations occurred in PTEN, CDKN2A/B, EGFR, RB1, and NPAS3, and the most frequent mutations were in P
Autor:
Jean-Pierre Delord, Seth M. Steinberg, Anna Spreafico, Anish Thomas, Raffit Hassan, Rastilav Bahleda, Ira Pastan, Carlos Gomez-Roca, Cody J. Peer, Gerhard Niederfellner, Jean-Charles Soria, Christine Alewine, Lillian L. Siu, William D. Figg, Antoine Italiano, Ulrik Lassen, Valerie Meresse Naegelen, Idrees Mian
Publikováno v:
Cancer. 126:4936-4947
Background LMB-100 is an antibody-toxin conjugate with an antimesothelin Fab linked to a 24-kilodalton portion of Pseudomonas exotoxin A with mutations that decrease immunogenicity. The objective of the current first-in-human phase 1 study was to det
Autor:
Angelica Fasolo, Antoine Italiano, Kert Viele, Gerald W. Prager, Richard Greil, Vivek Subbiah, Milind Javle, Patrick Y. Wen, Eduard Gasal, Giuseppe Curigliano, Jan H.M. Schellens, Aislyn Boran, Palanichamy Ilankumaran, Alexander Stein, Ulrik Lassen, Paul Burgess, Elena Elez, Filippo de Braud, Zev A. Wainberg
Publikováno v:
The Lancet Oncology. 21:1234-1243
Summary Background Effective treatments for patients with cholangiocarcinoma after progression on gemcitabine-based chemotherapy are urgently needed. Mutations in the BRAF gene have been found in 5% of biliary tract tumours. The combination of dabraf
Autor:
Shivaani, Kummar, Antoine, Italiano, Marcia S, Brose, Josh J, Carlson, Sean D, Sullivan, Ulrik, Lassen, Noah, Federman
Publikováno v:
The American journal of managed care. 28
The tropomyosin receptor kinase (TRK) family of proteins is encoded by neurotrophic tyrosine receptor kinase (NTRK) genes and has a role in the development and normal functioning of the nervous system. NTRK gene fusions have been identified as oncoge
Autor:
Josh J, Carlson, Antoine, Italiano, Marcia S, Brose, Noah, Federman, Ulrik, Lassen, Shivaani, Kummar, Sean D, Sullivan
Publikováno v:
The American journal of managed care. 28
Larotrectinib and entrectinib are tumor-agnostic tropomyosin receptor kinase (TRK) inhibitors that are indicated for the treatment of advanced or metastatic solid tumor cancers with neurotrophic tyrosine receptor kinase (NTRK) gene fusions. Regulator
Autor:
Christoffer Johansen, Annika von Heymann, Bolette S. Rafn, Signe Borgquist, Peer Christiansen, Peter Christensen, Robert Zachariae, Helle Pappot, Ulrik Lassen
Publikováno v:
Johansen, C, von Heymann, A, Rafn, B S, Borgquist, S, Christiansen, P, Christensen, P, Zachariae, R, Pappot, H & Lassen, U 2022, ' Late effects–the new focus of follow-up ', Acta Oncologica, vol. 61, no. 10, pp. 1163-1164 . https://doi.org/10.1080/0284186X.2022.2137845
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b79f278e075ec66a95c9339cfb2ce824
https://curis.ku.dk/ws/files/338172034/Late_effects_the_new_focus_of_follow_up.pdf
https://curis.ku.dk/ws/files/338172034/Late_effects_the_new_focus_of_follow_up.pdf
Autor:
Lise Bjerrum Thisted, Pernille Envold Bidstrup, Anne Frølich, Christiane Ehlers Mortensen, Susanne Oksbjerg Dalton, Helle Pappot, Katrine Loeppenthin, Christoffer Johansen, Lone Nørgaard Petersen, Ulrik Lassen, Elisabeth Wreford Andersen, Mikkel Bring Christensen, Jytte Ørsted
Publikováno v:
British Journal of Cancer
Loeppenthin, K, Dalton, S O, Johansen, C, Andersen, E, Christensen, M B, Pappot, H, Petersen, L N, Thisted, L B, Frølich, A, Mortensen, C E, Lassen, U, Ørsted, J & Bidstrup, P E 2020, ' Total burden of disease in cancer patients at diagnosis—a Danish nationwide study of multimorbidity and redeemed medication ', British Journal of Cancer, vol. 123, no. 6, pp. 1033-1040 . https://doi.org/10.1038/s41416-020-0950-3
Loeppenthin, K, Dalton, S O, Johansen, C, Andersen, E, Christensen, M B, Pappot, H, Petersen, L N, Thisted, L B, Frølich, A, Mortensen, C E, Lassen, U, Ørsted, J & Bidstrup, P E 2020, ' Total burden of disease in cancer patients at diagnosis—a Danish nationwide study of multimorbidity and redeemed medication ', British Journal of Cancer, vol. 123, no. 6, pp. 1033-1040 . https://doi.org/10.1038/s41416-020-0950-3
Background Multimorbidity is a growing challenge worldwide. In this nationwide study, we investigated the prevalence of multimorbidity and polypharmacy at the time of diagnosis across 20 cancers. Methods We conducted a nationwide register-based cohor
Autor:
Iben Spanggaard, Inge Marie Svane, Sine Reker Hadrup, Morten Hartvig Hansen, Vinicius Araujo Barbosa de Lima, Annie Borch, Arianna Draghi, Ulrik Lassen, Kristoffer Staal Rohrberg
Publikováno v:
Cytotherapy. 22:204-213
Background Immune checkpoint inhibitors (ICIs) have revolutionized the cancer therapeutic landscape and our perception of interactions between the immune system and tumor cells. Despite remarkable progress, disease relapse and primary resistance are